Commercial strategy · Investor & Portfolio Advisory

Test the commercial case. Build the growth plan.

Commercial due diligence and post-close growth advisory for investors in companies that sell to pharma and biotech. An operator's read on the market, the buyer, and whether the team can execute the plan.

Who it serves

Private equity and growth investors, their deal and value-creation teams, and the portfolio companies they back: commercialization and market access services, medical and scientific communications, data and analytics, HCP and patient engagement, and enterprise technology sold into life sciences.

Before the investment

The questions we answer.

01
Does the market pay?

Who holds the budget, what triggers the purchase, and what slows or stops it.

02
Does the buyer see the difference?

How the target's offer reads to the brand, access and commercial teams who choose between providers.

03
Can this team execute the plan?

Whether the go-to-market model, sales motion and capacity support the growth case in the hold period.

After the investment

What we build with management.

  • A prioritized growth agenda tied to the investment thesis.
  • Sharper positioning and offer structure for the buyers who matter most.
  • A sales motion and pipeline discipline the team can run.
  • Hands-on implementation, and fractional commercial leadership when the engagement calls for it.
Why Biomavens

We come from the operating side, with 30+ years across pharma commercial and market access, services businesses, and enterprise platforms sold into life sciences. We know how these buyers budget, decide and delay, and how the companies selling to them win or stall.

How we work

Each engagement is scoped to one investment or growth question and to the deal or value-creation timeline. The output is a written readout your team can act on.